A Randomized Parallel-Group Study to Evaluate the Efficacy and Tolerability of Two Dosing Regimens of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
Latest Information Update: 07 Apr 2023
At a glance
- Drugs Deuruxolitinib (Primary)
- Indications Alopecia areata
- Focus Therapeutic Use
- Sponsors Concert Pharmaceuticals
- 11 Aug 2020 Status changed from active, no longer recruiting to completed.
- 17 Sep 2019 According to a Concert Pharmaceuticals media release, topline data from this trial is expected in the first half of 2020.
- 17 Sep 2019 Status changed from recruiting to active, no longer recruiting, according to an Concert Pharmaceuticals media release.